CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor

Su Myat Phyu, Chih-Chung Tseng, Tim Andrew Davies Smith (Corresponding Author)

Research output: Contribution to journalArticle

7 Downloads (Pure)

Abstract

Purpose
Glycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.

Methods
Here, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.

Results
SB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.

Conclusion
SB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.
Original languageEnglish
Pages (from-to)227-235
Number of pages9
JournalMagnetic Resonance Materials in Physics, Biology and Medicine
Volume32
Issue number2
Early online date16 Nov 2018
DOIs
Publication statusPublished - Apr 2019

Fingerprint

Cytidine Diphosphate Choline
Glycogen Synthase Kinase 3
Colorectal Neoplasms
Breast Neoplasms
Lipids
Choline
Glucose
Magnetic Resonance Spectroscopy
Drug Delivery Systems
Cell Extracts
Lipid Metabolism
Phospholipids
Cell Cycle
Breast
Phosphotransferases
Neoplasms

Keywords

  • glycogen synthase kinase 3 (GSK3)
  • CDP-choline
  • 31P nuclear magnetic resonance spectroscopy
  • lipid
  • glucose
  • choline
  • Choline
  • Glycogen synthase kinase 3
  • 31 P nuclear magnetic resonance spectroscopy
  • Glucose
  • Lipid
  • APOPTOSIS
  • GLYCOGEN-SYNTHASE KINASE-3
  • TRANSPORT
  • METABOLISM
  • PATHWAY
  • PHOSPHATIDYLCHOLINE
  • P-31 nuclear magnetic resonance spectroscopy

Cite this

CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor. / Phyu, Su Myat; Tseng, Chih-Chung; Smith, Tim Andrew Davies (Corresponding Author).

In: Magnetic Resonance Materials in Physics, Biology and Medicine, Vol. 32, No. 2, 04.2019, p. 227-235.

Research output: Contribution to journalArticle

@article{08ff650b0ad64315aba972489694694c,
title = "CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor",
abstract = "PurposeGlycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.MethodsHere, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.ResultsSB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.ConclusionSB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.",
keywords = "glycogen synthase kinase 3 (GSK3), CDP-choline, 31P nuclear magnetic resonance spectroscopy, lipid, glucose, choline, Choline, Glycogen synthase kinase 3, 31 P nuclear magnetic resonance spectroscopy, Glucose, Lipid, APOPTOSIS, GLYCOGEN-SYNTHASE KINASE-3, TRANSPORT, METABOLISM, PATHWAY, PHOSPHATIDYLCHOLINE, P-31 nuclear magnetic resonance spectroscopy",
author = "Phyu, {Su Myat} and Chih-Chung Tseng and Smith, {Tim Andrew Davies}",
note = "Open via Springer Compact Agreement Funding from the University of Aberdeen Development Trust is gratefully acknowledged. Professor Zanda is gratefully acknowledged for the use of his NMR system.",
year = "2019",
month = "4",
doi = "10.1007/s10334-018-0719-3",
language = "English",
volume = "32",
pages = "227--235",
journal = "Magnetic Resonance Materials in Physics, Biology and Medicine",
issn = "0968-5243",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor

AU - Phyu, Su Myat

AU - Tseng, Chih-Chung

AU - Smith, Tim Andrew Davies

N1 - Open via Springer Compact Agreement Funding from the University of Aberdeen Development Trust is gratefully acknowledged. Professor Zanda is gratefully acknowledged for the use of his NMR system.

PY - 2019/4

Y1 - 2019/4

N2 - PurposeGlycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.MethodsHere, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.ResultsSB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.ConclusionSB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.

AB - PurposeGlycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.MethodsHere, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.ResultsSB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.ConclusionSB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.

KW - glycogen synthase kinase 3 (GSK3)

KW - CDP-choline

KW - 31P nuclear magnetic resonance spectroscopy

KW - lipid

KW - glucose

KW - choline

KW - Choline

KW - Glycogen synthase kinase 3

KW - 31 P nuclear magnetic resonance spectroscopy

KW - Glucose

KW - Lipid

KW - APOPTOSIS

KW - GLYCOGEN-SYNTHASE KINASE-3

KW - TRANSPORT

KW - METABOLISM

KW - PATHWAY

KW - PHOSPHATIDYLCHOLINE

KW - P-31 nuclear magnetic resonance spectroscopy

UR - http://www.mendeley.com/research/cdpcholine-accumulation-breast-colorectal-cancer-cells-treated-gsk3targeting-inhibitor

UR - https://abdn.pure.elsevier.com/en/en/researchoutput/cdpcholine-accumulation-in-breast-and-colorectal-cancer-cells-treated-with-a-gsk3targeting-inhibitor(08ff650b-0ad6-4315-aba9-72489694694c).html

U2 - 10.1007/s10334-018-0719-3

DO - 10.1007/s10334-018-0719-3

M3 - Article

VL - 32

SP - 227

EP - 235

JO - Magnetic Resonance Materials in Physics, Biology and Medicine

JF - Magnetic Resonance Materials in Physics, Biology and Medicine

SN - 0968-5243

IS - 2

ER -